MedTrace Logo

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

NCT04156698 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2023-08-09

No results posted yet for this study

Summary

This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study.

Conditions

  • Hypopharyngeal Carcinoma
  • Immunotherapy
  • Chemotherapy

Interventions

DRUG

Docetaxel

Docetaxel is a chemotherapy drug.

DRUG

Cisplatin

Cisplatin is a chemotherapy drug.

DRUG

Capecitabine

Capecitabine is a chemotherapy drug.

DRUG

Camrelizumab

Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Liang Zhou, PhD. · Eye & ENT Hospital, Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2023-04-16
Completion
2026-01-16

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04156698 on ClinicalTrials.gov